Table 1.
Patients demographics, clinical and pathological characteristics
| Characteristic | (n = 30) |
|---|---|
| Age (years), median (IQR) | 68 (62–70) |
| BMI (kg/m2), median (IQR) | 25 (23–26) |
| CCI (Age adjusted), n (%) | |
| ≤ 2 | 17 (56) |
| > 2 | 13 (44) |
| PSA at biopsy (ng/mL), median (IQR) | 8.5 (4.6–16) |
| PSA density (MRI) (ng/mL/mL), median (IQR) | 0.28 (0.18–0.48) |
| Clinical stage, n (%) | |
| cT1 | 9 (30) |
| cT2 | 15 (50) |
| > cT2 | 6 (20) |
| Prostate biopsy approach, n (%) | |
| Systematic | 12 (40) |
| MRI targeted + systematic | 18 (60) |
| Prostate biopsy cores, median (IQR) | |
| Number of overall cores | 15 (14–16) |
| Number of positive cores | 8 (6–10) |
| Number of systematic cores | 12 (12–14) |
| Number of positive systematic cores | 6 (3–8) |
| Number of MRI targeted cores | 3 (2–3) |
| Number of positive MRI targeted cores | 2 (1–3) |
| Biopsy Grade Group, n (%) | |
| 2 (3 + 4) | 2 (7) |
| 3 (4 + 3) | 12 (40) |
| 4 (4 + 4) | 13 (43) |
| 5 (4 + 5 or 5 + 4) | 3 (10) |
| EAU risk group, n (%) | |
| Localized, intermediate risk | 11 (37) |
| Localized, high risk | 16 (53) |
| Locally advanced | 3 (10) |
| Risk of LNI according to the Briganti 2019 nomogram (median, IQR) | 18 (7–53) |
| [68 Ga]Ga-PSMA-11 PET/MRI and PET/CT, n of positive patients (%) | |
| Number of patients | 22 (100) |
| Median activity, MBq (IQR) | 155 (120–203) |
| Prostate | 22 (100) |
| Pelvic lymph nodes | 2 (9) |
| [18F]F-PSMA-1007 PET/MRI and PET/CT, n of positive patients (%) | |
| Number of patients | 8 (100) |
| Median activity, MBq (IQR) | 294 (258–360) |
| Prostate | 8 (100) |
| Pelvic lymph nodes | 5 (63) |
| [99mTc]Tc-PSMA-I&S SPECT/CT, n of positive patients (%) | |
| Median activity, MBq (IQR) | 734 (730–738) |
| Prostate | 29 (97) |
| Pelvic lymph nodes | 6 (20) |
| Tumor stage, n (%) | |
| pT2c | 9 (30) |
| pT3a | 15 (50) |
| pT3b | 6 (20) |
| Pathological Grade Group, n (%) | |
| 3 (4 + 3) | 8 (27) |
| 4 (4 + 4) | 12 (40) |
| 5 (4 + 5 or 5 + 4) | 10 (33) |
| Surgical margins, n (%) | |
| Negative | 24 (80) |
| Positive | 6 (20) |
| Number of removed nodes (median, IQR) | 22 (18–31) |
| Pathological N stage (%) | |
| pN0 | 21 (70) |
| pN1 | 9 (30) |
IQR: Interquartile Range; BMI: Body Mass Index; CCI: Charlson Comorbidity Index; MRI: Multiparametric Resonance Imaging; EAU: European Association of Urology